Mount Yale Investment Advisors LLC Cuts Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Mount Yale Investment Advisors LLC decreased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 62.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,673 shares of the biopharmaceutical company's stock after selling 9,305 shares during the period. Mount Yale Investment Advisors LLC's holdings in Halozyme Therapeutics were worth $271,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. SWP Financial LLC purchased a new position in Halozyme Therapeutics during the fourth quarter valued at $366,000. Marshall Financial Group LLC purchased a new position in shares of Halozyme Therapeutics during the fourth quarter valued at about $1,530,000. First Citizens Bank & Trust Co. increased its holdings in shares of Halozyme Therapeutics by 16.9% in the fourth quarter. First Citizens Bank & Trust Co. now owns 4,704 shares of the biopharmaceutical company's stock worth $225,000 after purchasing an additional 681 shares during the last quarter. Janney Montgomery Scott LLC increased its holdings in shares of Halozyme Therapeutics by 698.8% in the fourth quarter. Janney Montgomery Scott LLC now owns 287,731 shares of the biopharmaceutical company's stock worth $13,756,000 after purchasing an additional 251,711 shares during the last quarter. Finally, Sugar Maple Asset Management LLC purchased a new stake in shares of Halozyme Therapeutics in the fourth quarter worth about $373,000. Hedge funds and other institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Trading Up 1.1 %

Halozyme Therapeutics stock traded up $0.59 during midday trading on Thursday, reaching $56.42. The stock had a trading volume of 1,058,591 shares, compared to its average volume of 1,401,331. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. The firm has a market cap of $7.18 billion, a price-to-earnings ratio of 18.68, a price-to-earnings-growth ratio of 0.42 and a beta of 1.24. Halozyme Therapeutics, Inc. has a 52-week low of $33.15 and a 52-week high of $65.53. The company has a fifty day moving average of $50.28 and a 200 day moving average of $54.28.

Wall Street Analyst Weigh In

A number of analysts have issued reports on HALO shares. Cowen reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Piper Sandler boosted their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a research report on Friday, January 10th. JMP Securities upped their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a "market outperform" rating in a research note on Friday, November 1st. HC Wainwright lifted their price objective on shares of Halozyme Therapeutics from $68.00 to $70.00 and gave the stock a "buy" rating in a research note on Friday, January 10th. Finally, Wells Fargo & Company decreased their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $60.89.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 10,000 shares of the company's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the transaction, the director now directly owns 43,611 shares in the company, valued at $2,180,986.11. This represents a 18.65 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 2.40% of the company's stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.